Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,087 INR | +0.67% | +4.57% | +27.28% |
06:09am | Glenmark Pharmaceuticals Gets US FDA's Final Approval for Generic Pain Relief Medicines | MT |
Apr. 25 | Glenmark Lifesciences' Net Profit Slides in Fiscal Q4 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+27.28% | 3.65B | |
+21.01% | 43.34B | |
+20.44% | 21.96B | |
+10.86% | 14.09B | |
+12.42% | 13.64B | |
+38.85% | 11.43B | |
-8.59% | 6.86B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+8.46% | 5.22B |
- Stock Market
- Equities
- GLENMARK Stock
- News Glenmark Pharmaceuticals Limited
- Glenmark Pharmaceuticals Unit Licenses Spanish Firm to Develop Autoimmune Diseases Antibody ISB 880